Review
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jan 27, 2022; 14(1): 62-79
Published online Jan 27, 2022. doi: 10.4254/wjh.v14.i1.62
Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response
Sara Cuesta-Sancho, Mercedes Márquez-Coello, Francisco Illanes-Álvarez, Denisse Márquez-Ruiz, Ana Arizcorreta, Fátima Galán-Sánchez, Natalia Montiel, Manuel Rodriguez-Iglesias, José-Antonio Girón-González
Sara Cuesta-Sancho, Mercedes Márquez-Coello, Francisco Illanes-Álvarez, Denisse Márquez-Ruiz, Ana Arizcorreta, José-Antonio Girón-González, Medicina Interna, Hospital Universitario Puerta del Mar, Facultad de Medicina, Universidad de Cádiz, Instituto para la Investigación e Innovación en Ciencias Biomédicas de Cádiz (INiBICA), Cádiz 11009, Spain
Fátima Galán-Sánchez, Natalia Montiel, Manuel Rodriguez-Iglesias, Microbiología, Hospital Universitario Puerta del Mar, Facultad de Medicina, Universidad de Cádiz, Instituto para la Investigación e Innovación en Ciencias Biomédicas de Cádiz (INiBICA), Cádiz 11009, Spain
Author contributions: Cuesta-Sancho S and Márquez-Coello M are equal contributions; Cuesta-Sancho S, Márquez-Coello M, Girón-González JA wrote the draft; All authors conceived and designed, analyzed the data; all authors contributed to critical revision of the manuscript, and saw and approved the final version.
Supported by Consejería de Salud, Junta de Andalucía, Integrated Territorial Initiative for the province of Cádiz, No. (ITI) 2014-2020; Cofinanced by Fondo Europeo de Desarrollo Regional (FEDER), No. PI-0076-2017; Consejería de Salud, Junta de Andalucía, No. PI 0128/2018; and Instituto de Salud Carlos III, Ministerio de Sanidad, Acción Estratégica en Salud 2017-2020, No. PI19/01361.
Conflict-of-interest statement: All authors reported no conflicts.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: José-Antonio Girón-González, MD, PhD, Doctor, Medicina Interna, Hospital Universitario Puerta del Mar, Facultad de Medicina, Universidad de Cádiz, Instituto para la Investigación e Innovación en Ciencias Biomédicas de Cádiz (INiBICA), Avda Ana de Viya, s/n, Cádiz 11009, Spain. joseantonio.giron@uca.es
Received: March 6, 2021
Peer-review started: March 6, 2021
First decision: July 27, 2021
Revised: August 2, 2021
Accepted: December 9, 2021
Article in press: December 9, 2021
Published online: January 27, 2022
Core Tip

Core Tip: The excellent hepatitis C virus (HCV) response to direct acting agents should not obviate certain obstacles to eradicate this pathology, especially the loss to follow-up and the possibility of reinfections. Chronic hepatitis C determines persistent alterations despite the elimination of HCV, such as liver dysfunction and continued risk of decompensation and hepatocarcinoma, especially in subjects treated in advanced stages of the disease. Weight gain after sustained virological response (SVR) may favor liver steatosis, increasing the risk of progression of hepatic disease. The probability of complications after SVR in human immunodeficiency virus coinfected patients is similar to that of those HCV-monoinfected.